Indivior Pharmaceuticals, Inc.
INDV- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001625297
In the last 90 days, Indivior Pharmaceuticals, Inc. insiders filed 2 open-market purchases and 1 sale; 337 institutions reported holding it in 13F filings for Q2 2026, worth $4.98B in total; Oaktree Capital is the only superinvestor holding it.
Q1 2024 vs. Q4 2023
How the institutions holding Indivior Pharmaceuticals, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 76 | 95 | +19 |
| Shares | 64.4M | 67.5M | +3.07M (+4.8%) |
| Value | $974.7M | $1.38B | +$406.7M (+41.7%) |
New holders (25)
Institutions that held Indivior Pharmaceuticals, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
Sold out (6)
Institutions that held Indivior Pharmaceuticals, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Jupiter Asset Management Ltd | 358,745 | $5.42M |
| Campbell & CO Investment Adviser LLC | 37,948 | $573.1K |
| Chilton Investment Co LLC | 17,230 | $204.2K |
| BlackRock Inc. | 82 | $1.25K |
| McClarren Financial Advisors, Inc. | 86 | $1.00K |
| Vima LLC | 50 | $764 |